Stay updated with breaking news from Drug Selection. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
AstraZeneca will highlight new data across its Vaccines and Immune Therapies portfolio at the 33rd European Congress of Clinical Microbiology
FDA accepts nirsevimab application as first protective option against RSV disease for all infants Nirsevimab would be the first broadly protective option against RSV disease designed for all infants, if approvedNirsevimab delivered consistent protection of approximately 80% against medically attended RSV diseas...
FDA accepts nirsevimab application as first protective option against RSV disease for all infants Nirsevimab would be the first broadly protective option against RSV disease designed for all infants
Investegate announcements from AstraZeneca PLC, Beyfortus (nirsevimab) approved in EU
AstraZeneca's Beyfortus recommended for approval in the EU by CHMP